Sanofi India Limited hosted an Investor/Analyst Call on February 26, 2026, to discuss financial results for the quarter and year ended December 31, 2025. Management highlighted a pivotal transformation focusing on an R&D-driven, AI-enabled biopharma model. Despite domestic sales being flat for 2025, Profit Before Tax (PBT) grew by 1%, driven by operational efficiency and the stabilizing diabetes franchise.
Sanofi India’s Year of Transformation
Deepak Arora, Managing Director, welcomed participants to the investor call covering the financial results for the quarter and year ended December 2025. He framed the past year as a “year of transformation”, centered on modernizing the business model to achieve sustainable and profitable growth. This modernization involves three key components: business model transformation into an R&D-driven, AI-enabled biopharma organization; adopting patient-centric and digital capabilities; and growing the legacy portfolio via a partnership model.
Financial Highlights and Partnership Impact
Rachid Ayari, CFO, discussed the complexities arising from the demerger of the Consumer Health business in 2024 and the signature of key partnerships in Q1 2024 and July 2025. He noted that total net sales for domestic operations in 2025 stood at INR 1,511 crores, with diabetes comprising about half. The partnership segment saw a slight decline of minus 2% year-on-year, attributed mainly to stock movement and frozen periods related to partner agreements. Despite top-line impacts, the company achieved plus 1% growth in PBT for the full year, showcasing efficiency gains.
Diabetes Segment Leadership
Mr. Arora reiterated Sanofi’s leadership in the insulin segment. The flagship brand, Lantus, maintained 31% market leadership in the basal segment with a volume acceleration of plus 6%. Toujeo, the preferred second-generation basal insulin, achieved double-digit growth. Management emphasized leveraging the partnership model to capture growth in the public sector and maintaining momentum in the expanding GLP-1 market.
Innovation and Pipeline Focus
The R&D focus was highlighted, referencing the completed LANDMARC real-world evidence study involving nearly 6,000 patients. The company is also advancing pipeline products, including Phase II and Phase III studies for teplizumab, Brivekimig, and Frexalimab. Furthermore, Sanofi is looking to launch a novel pen, potentially integrating digital solutions for better adherence.
CSR Initiatives and Outlook
Mr. Arora proudly detailed the company’s expanded CSR efforts, including community programs focused on diabetes in schools, outreach initiatives impacting over 232,000 students, and Mobile Medical Units reaching 1.1 million beneficiaries in Maharashtra. Regarding the full-year performance, the insulin portfolio saw overall growth of plus 6%, accelerating to nearly 11% growth in Q4 alone.
Analyst Q&A Key Takeaways
- Partnership Volatility: Management explained quarterly fluctuations in partnership sales (e.g., the drop from INR 200 crores in Q3 to INR 153 crores in Q4) were due to inventory stock stabilization and replenishment cycles, not fundamental business issues.
- Future Growth Focus: The immediate strategy remains focused on diabetes and insulin, aiming to accelerate double-digit growth for Soliqua, which combines glargine and GLP-1.
- Portfolio Expansion: For 2026, no new therapeutic area entries are planned for the listed entity; focus remains on maximizing the established portfolio and partnership stabilization.
- Margin Queries: Management noted that while diabetes and partnership margins were largely intact, overall margins were impacted by phasing and top-line movements. The company expects the partnership segment to stabilize by the end of 2026.
Mr. Arora concluded by emphasizing the focus on growth, stabilizing the partnership, and maximizing the value derived from the pivotal transformation year to ensure sustainable and profitable growth moving into 2026.
Source: BSE
